Enzalutamid v liečbe metastatického kastračne rezistentného karcinómu prostaty – kazuistika // SOLEN

Onkológia S1/2026

Enzalutamid in the treatment of metastatic castration- resistant prostate cancer – case report

Introduction: Enzalutamide is a highly effective non-steroidal androgen receptor inhibitor that, according to the AFFIRM study, significantly prolongs overall survival in patients with metastatic castration- resistant prostate cancer (mCRPC) following chemotherapy.

Case report: The presented case report of a 76-year-old patient confirms the long-term efficacy of enzalutamide, with achievement of partial regression of metastatic lesions, a decrease in PSA to 0.05 ng/ml, and good treatment tolerance without serious adverse effects. Conclusion: Enzalutamide represents an established standard of care in the treatment of mCRPC, demonstrably prolonging overall survival and radiographic progression-free survival (rPFS) in patients both before and after chemotherapy.

Keywords: metastatic castration- resistant prostate cancer, treatment, enzalutamide